Novo CEO Brushes Off Post-Midterm Drug-Pricing Fears, Says ‘Our World’ Won’t Change Dramatically – NVO Stock Gains Pre-Market

CEO Mike Doustdar told CNBC that while the company has experienced weak growth in the past due to pricing, volumes have grown ‘phenomenally.’ ...

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (stocktwits.com)